about
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma.Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesThe proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.Role of Galectins in Multiple Myeloma.Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.Possible targets to treat myeloma-related osteoclastogenesis.Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.Neurofibromatosis type I and multiple myeloma coexistence: A possible link?Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocationsBone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patientsLow bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cellsBone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma PatientsLoss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in OsteoclastsThe transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchangedApplication of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
P50
Q33574203-0CB0E8F1-E82A-4598-89B5-9A1995DA1D03Q38685897-EBF8D7E0-ED90-410F-BC1F-E1B4DD4D6804Q38764048-1C3CD0C7-1F60-453B-9164-8AFA467E371EQ38766239-B9CDA97B-C17E-42D1-90AE-ACF7E78CF2A2Q39205798-19BB2979-94BB-431E-AA31-BF7CC1095969Q39239701-4BC64B44-325B-47FE-B41B-B16925407EDEQ39616165-E8C67E46-24C0-4519-A580-959DF509B83BQ41191920-508CD9E3-ACA1-4C48-958A-E7BA3EC54608Q41593035-3E1D74FB-17C9-4391-9BB0-5414AE3B0CEBQ42846656-5B2CC042-256C-4C4A-8939-7C9E9EDAC477Q42923841-E0198446-DA38-45EA-81DA-0A0D5D454D83Q43409324-C6DF231C-176C-4256-B047-87E66BAB24DCQ44774590-2E0C3C7E-B4BA-4DC5-A089-0D3BE8F93367Q46410066-E660E298-57DD-42ED-967C-E5E9E1D08694Q47282400-5490EB02-CC7D-49B1-BD5D-400B39287869Q48294981-61631506-27E3-45EA-8F6D-F6F606395C48Q48323207-B376FEFA-6DBF-4C16-AE14-DDAEC97B3E86Q50912108-D5DFDA6D-87C3-4F9E-B38D-B794FA0A7435Q52678864-AEDFF5F1-055A-4A3A-931F-0315720727EAQ54301591-3532AA7A-16D4-447E-ADA2-E243F99D4AFFQ54422075-16A71C82-F5B0-481B-96DF-CE34F5AE5696Q54940448-437FB877-ADE2-486E-BA3F-F7484ED24740Q60197153-94AC1962-3090-46AA-8652-C801306D499BQ60197156-A02D6DD6-333D-4682-8F9B-A71FF0AEA67AQ60197167-0026E82A-BA8C-46C4-88CC-25D5F88C856DQ64055877-022A4E71-82C8-48EF-8522-5AEDC1632EE0Q64108089-DFA9C36C-E725-417F-868B-D39FA19C1028Q92205678-F3A6A1A4-4C98-490A-9AD0-E9EB9F2B9746Q95831388-3A2F7DDB-818C-4BBE-BADF-EDBFDF6ECCA3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paola Storti
@ast
Paola Storti
@en
Paola Storti
@es
Paola Storti
@nl
Paola Storti
@sl
type
label
Paola Storti
@ast
Paola Storti
@en
Paola Storti
@es
Paola Storti
@nl
Paola Storti
@sl
prefLabel
Paola Storti
@ast
Paola Storti
@en
Paola Storti
@es
Paola Storti
@nl
Paola Storti
@sl
P1053
M-2015-2013
P106
P1153
25226226100
P21
P31
P3829
P496
0000-0001-8014-8205